Take Solutions Peer Comparison

NSE: TAKE | BSE: 532890

₹16.14

₹-0.84 (-4.95%)

As on 28-Aug-2026IST

Market cap

₹241 Cr

Revenue (TTM)

₹85 Cr

P/E Ratio

18.8

P/B Ratio

7.5

Div. Yield

0 %

Edit

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Market cap (₹ Cr)	241	2,746	269	40	9
Revenue (₹ Cr)	85	2,901	138	55	0
Net Profit (₹ Cr)	12.82	16.16	-9.39	-2.86	0.02
Net Margin (%)	6.38	0.55	-6.66	-5.15	9.72
RoE (%)	20.84	0.29	-9.20	-16.06	0.53
Price to Earnings	18.78	169.93	--	--	419.92
Price-To-Book	7.51	0.41	2.85	0.44	2.24

Income Statement (₹ Cr)

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Operating Revenue	84.56	2,901.49	137.73	55.10	0.22
Total Income	92.53	2,950.84	141.01	55.46	0.22
Total Expenditure	86.29	2,416.46	140.53	34.09	0.18
EBITDA	-1.73	485.03	-2.80	21.01	0.04
Depreciation	0.01	348.02	8.36	11.51	0.00
EBIT	-1.74	137.01	-11.16	9.50	0.03
Interest	0.18	168.51	3.32	5.58	0.00
Other Income	7.97	49.35	3.29	0.36	0.00
Exceptional Items	0.00	-2.84	0.00	-0.61	0.00
Profit before Tax	6.06	15.01	-11.19	3.67	0.03
Provision for Tax	0.16	-1.15	-1.80	6.53	0.01
Profit after Tax	5.90	16.16	-9.39	-2.86	0.02

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Shareholder's Funds	31.00	6,676.90	92.39	93.16	3.93
Minority Interest	0.00	0.00	0.49	0.00	0.00
Non-Current Liabilities	0.00	2,929.36	29.81	55.04	0.00
Current Liabilities	5.24	2,317.05	53.90	30.23	0.32
Total Liabilities	36.48	9,986.90	176.20	143.23	4.36

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Non-Current Assets	0.00	8,580.12	88.99	149.74	1.55
Current Assets	23.77	2,842.10	63.28	28.42	2.70
Total Assets	36.48	9,986.90	176.20	143.23	4.36
Total Debt*	0.00	2,083.91	38.00	54.03	0.00
Net Current Assets	18.53	525.05	9.38	-1.82	2.38
Contingent Liabilities	74.49	423.42	26.88	--	--

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Cash From Operating Activities	-16.37	375.23	1.90	11.83	0.03
Cash Flow from Investing Activities	22.21	-192.21	-11.80	-15.84	0.01
Cash from Financing Activities	-3.24	-102.09	5.29	3.90	--
Net Cash Inflow / Outflow	2.60	80.93	-4.60	-0.11	0.04

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
ROCE (%)	13.63	2.31	10.01	12.63	11.87
ROE (%)	20.84	0.29	-9.20	-16.06	0.53
ROA (%)	16.23	0.15	-5.35	-1.78	0.49
EBIT Margin (%)	-2.05	4.72	-8.10	17.24	14.35
Net Margin (%)	6.38	0.55	-6.66	-5.15	9.72
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Revenue Growth (%)	-100.00	0.20	-2.60	12.34	-72.27
EBIT Growth (%)	67.89	-50.39	-203.38	-22.16	-90.43
Net Profit Growth (%)	81.10	-84.49	-222.82	-133.81	-91.46
EPS Growth (%)	81.10	-85.24	-218.89	-230.45	-91.46
Book Value Growth (%)	331.34	3.63	76.48	30.20	10.05

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Price / Earnings	40.81	147.54	-29.77	-2.65	419.92
Price / Book Value	7.51	0.41	2.85	0.44	2.24
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-137.15	8.86	-112.98	4.44	250.66
Market Cap (₹ Cr)	--	3,411.88	360.30	58.31	17.90

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Debt to Equity	0.00	0.23	0.25	0.50	0.00
Short term debt to equity ratio	--	0.11	0.14	0.15	--
Current Ratio	4.54	1.23	1.17	0.94	8.40
Quick Ratio	4.54	0.79	0.92	0.67	7.52
Interest Coverage	35.64	1.09	-2.37	1.66	2,845.31

	Take Solutions	Dishman Carbogen	Lyka Labs	Vivo Bio Tech	Genomic Biotech
Debtors to sales (%)	0.26	23.19	25.44	21.32	1,073.15
Asset Turnover	2.33	0.26	0.79	0.34	0.05
Receivable days	--	77.38	92.33	90.11	1,026.01
Inventory Days	--	120.02	29.04	64.77	122.93
Payable days	--	172.74	88.82	64.32	554.30
Cash Conversion Cycle	--	24.66	32.55	90.56	594.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.